+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Liver Cancer Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)

  • ID: 4591194
  • Report
  • April 2019
  • Region: Global
  • 115 pages
  • Mordor Intelligence
until Jun 30th 2020
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now


  • ArQule Inc.
  • Bayer AG
  • Celsion Corp.
  • Eisai Inc.
  • Exelixis, Inc
  • F. Hoffmann-La Roche Ltd
  • MORE
Market Overview

The liver cancer therapeutics market is expected to register a CAGR of nearly 8.00% during the forecast period, 2019-2024. The major factors for the growth of the liver cancer therapeutics market include the rising prevalence of liver cancer, increasing R&D investments for the development of novel therapies, and government initiatives to increase cancer awareness.
  • The change in the current lifestyle has led to the exposure of a large amount of population to certain risk factors that contribute to liver cancer. The risk factors include hepatitis (caused by either the hepatitis B or hepatitis C virus), type 2 diabetes, metabolic disorders, and excess body weight, alcohol consumption, and tobacco smoking.
  • Liver cancer risk increases substantially with the increase in one’s body mass index (BMI). More than half of the adult population in the United States falls under the category referred to as overweight. Moreover, the high demand for therapeutic drugs for liver cancer along with the above-mentioned factor creates wide opportunities for the manufacturers to produce more drugs and thereby, create a competitive landscape.
  • The American Cancer Society had stated that there would be 29,000 cases of cancer death in the United States in 2017. Liver cancer incidence has been rising in the United States since the mid-1970s, and is expected to continue to grow until 2030.
  • Thus, owing to the increasing prevalence of liver cancer, the market is expected to witness a high CAGR over the forecast period.
Scope of the Report

Liver cancer is cancer that begins in the liver cells and the therapies used in the treatment of liver cancer are covered under this report. The market is segmented by type, therapy, and geography.

Key Market Trends

Hepatocellular Carcinoma is the Segment by Type is expected to be the Fastest Growing Segment

Hepatocellular carcinoma (HCC) is the most common form of liver cancer, which mostly occurs in people suffering from chronic liver diseases, like cirrhosis. Hepatocellular carcinoma is one of the major causes leading to cancer-related deaths worldwide. It is observed that the Asian and African countries have higher incidence rates of hepatocellular carcinoma than the developed world, due to the disparity in the major risk factors causing hepatocellular carcinoma, such as hepatitis C virus (HCV) and hepatitis B virus (HBV) infection in those regions. As per the data published by the National Organization for Rare Diseases (NORD), there are approximately six new cases of HCC per every 100,000 people in the general population of the United States. With the increase in the incidence of hepatocellular carcinoma, there is expected to be a huge demand for the liver cancer therapeutics. Hence, the rising incidence of cancer and high unmet medical needs are the major factors that drive the market in the forecast period.

North America is Expected to Dominate the Market

North America is expected to dominate the market, due to the presence of better healthcare infrastructure and rising geriatric population. According to the estimates of American Society of Clinical Oncology, there are 42,220 adults who are diagnosed with liver cancer in the United States in 2018, (of which there are 30,610 men and 11,610 women). According to the Center for Disease Control and Prevention (CDC), 32,908 new cases of liver cancer were identified in 2015 in the United States, of which, the death toll was 25,760. It is observed that for every 100,000 people, 8 new liver cancer cases, and 7 deaths were registered. Hence, the incidence of liver cancer in the United States has increased during 2015-2018. This is leading to an increasing demand for liver cancer treatment, which, in turn, is driving the market in the forecast period.

Competitive Landscape

The market studied is a consolidated market, owing to the presence of a few major market players. Market players are focusing on R&D to bring innovative treatments for the treatment of liver cancer. Some of the market players are ArQule Inc., Bayer AG, Bristol‑Myers Squibb Company, Celsion Corp., Eisai Inc., Exelixis Inc, F. Hoffmann-La Roche Ltd, and Merck & Co. Inc.
Note: Product cover images may vary from those shown
2 of 4


  • ArQule Inc.
  • Bayer AG
  • Celsion Corp.
  • Eisai Inc.
  • Exelixis, Inc
  • F. Hoffmann-La Roche Ltd
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Liver Cancer
4.2.2 Increasing R&D investments for the development of novel therapies
4.2.3 Government Initiatives to Increase the Cancer Awareness
4.3 Market Restraints
4.3.1 Side Effect associated with Medication
4.3.2 Stringent regulatory Policies for Therapeutics
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Type
5.1.1 Hepatocellular Carcinoma
5.1.2 Cholangio Carcinoma
5.1.3 Hepatoblastoma
5.1.4 Other
5.2 By Therapy
5.2.1 Targeted Therapy
5.2.2 Radiation Therapy
5.2.3 Immunotherapy
5.2.4 Chemotherapy
5.2.5 Other
5.3 Geography
5.3.1 North America US Canada Mexico
5.3.2 Europe Germany UK France Italy Spain Rest of Europe
5.3.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 ArQule Inc.
6.1.2 Bayer AG
6.1.3 Bristol-Myers Squibb Company
6.1.4 Celsion Corp.
6.1.5 Eisai Inc.
6.1.6 Exelixis, Inc
6.1.7 F. Hoffmann-La Roche Ltd
6.1.8 Merck & Co., Inc.

Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • ArQule Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Celsion Corp.
  • Eisai Inc.
  • Exelixis, Inc
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
Note: Product cover images may vary from those shown